1. Home
  2. UTSI vs EVAX Comparison

UTSI vs EVAX Comparison

Compare UTSI & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo UTStarcom Holdings Corp.

UTSI

UTStarcom Holdings Corp.

N/A

Current Price

$2.27

Market Cap

22.3M

ML Signal

N/A

Logo Evaxion Biotech

EVAX

Evaxion Biotech

N/A

Current Price

$3.02

Market Cap

25.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
UTSI
EVAX
Founded
1991
2008
Country
China
Denmark
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.3M
25.9M
IPO Year
1999
2020

Fundamental Metrics

Financial Performance
Metric
UTSI
EVAX
Price
$2.27
$3.02
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$11.67
AVG Volume (30 Days)
5.9K
197.0K
Earning Date
03-24-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$328.20
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.00
$2.52
52 Week High
$3.63
$12.15

Technical Indicators

Market Signals
Indicator
UTSI
EVAX
Relative Strength Index (RSI) 39.77 49.08
Support Level $2.00 $2.91
Resistance Level $2.60 $3.62
Average True Range (ATR) 0.11 0.27
MACD -0.01 -0.02
Stochastic Oscillator 47.80 33.33

Price Performance

Historical Comparison
UTSI
EVAX

About UTSI UTStarcom Holdings Corp.

UTStarcom Holdings Corp is engaged in providing telecommunication and networking products, solutions and services, focusing on optical networking, carrier-class packet optical, network synchronization, broadband products and a Software Defined Networking (SDN) platform optimized for AI networking infrastructure, mobile backhaul, metro aggregation, broadband access and value-added services. The Company operates through two segments: Equipment, which includes the sale of network infrastructure and application products such as broadband and wireless infrastructure technologies, and Services, which generates maximum revenue and provides support and operational services for equipment products. The Company generates maximum revenue from Japan.

About EVAX Evaxion Biotech

Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.

Share on Social Networks: